Affymetrix Shares Plunge Following Revenue, Earnings Warning | GenomeWeb

NEW YORK, June 12 – Affymetrix stock was down $14.10, or 34 percent, at $26.85 in afternoon trading on Tuesday, following an announcement on Monday after the close of trading that the company was slashing its second quarter revenue expectations.

The company said its revenues for the quarter would total between $44 million and $50 million, a drop of between $6 million and $14 million from previous estimates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.